ÑÇÉ«Ó°¿âapp

Dr. Seder is currently Acting Associate Director and Chief of the Cellular Immunology Section. Dr. Seder's laboratory has focused on the cellular and molecular mechanisms by which vaccines and adjuvants mediate protective immunity in mouse, and non-human primate models of HIV, malaria, tuberculosis, and cancer. His work was first to show that multi-functional T cells were correlated with vaccine mediated protection against various infections. He has also shown the importance of the intravenous route of vaccination in generating tissue resident T cells for protection against malaria and TB in pre-clinical animal models. Based on this work, Dr. Seder led the first in human clinical studies using intravenous vaccination to generate protective immunity with an attenuated malaria vaccine that was highly protective. Dr. Seder has also developed a personalized nanoparticle neoantigen vaccine that has been licensed for clinical trials and conceptualized a new paradigm termed “Vax-Innate “to harness the ability of the vaccines to enhance T cell immunity as well as alter the tumor microenvironment to facilitate tumor clearance. Dr. Seder was intimately involved with his colleagues at The Vaccine Research Center in the development of the Moderna mRNA vaccine against COVID and was a member of Operation Warp Speed. His work provided the pre-clinical data for demonstrating safety and efficacy of the Moderna vaccine prior to the initiation of the Phase 3 study in humans and provided the scientific basis for boosting against variants. Over the past several years Dr. Seder has led global development of using a monoclonal antibody to prevent malaria infection across all ages in Africa.